# Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

> **NCT00790192** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 488 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone
- **DRUG:** Lurasidone
- **DRUG:** Quetiapine XR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00790192
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790192, "Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00790192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*